Seegene unveils ADLM's unmanned PCR automation system and diagnostic data analysis platform.
Jul 24, 2025
|
CURECA™ is the world's first system to fully automate the entire PCR test process, and all steps from sample storage, pretreatment, nucleic acid extraction, amplification, and result analysis are carried out without human intervention. The system can be inspected for 24 hours in a row, and human errors are minimized, greatly increasing the consistency and reliability of the test results.
In particular, a preprocessing module, CURECA™ Prep (Cureka Prep), fundamentally solved the 'Manual preprocessing' problem, which was the biggest burden in conventional laboratories. However, CURECA™ is expected to automate all of these laboratory challenges for the first time in the world to minimize inspection personnel while overcoming limitations in sample processing and testing and securing economic efficiency.
In addition, CURECA™ Prep is expected to dramatically increase the level of automation in the overall diagnostic market as it can be applied to other diagnostic fields such as biochemistry and immunodiagnosis in addition to PCR. It has a modular structure that allows for free combination and placement according to the laboratory environment, so it can be applied to laboratories of various sizes and conditions.
STAGORA™, which will be released by Seegene, is a statistical platform that collects and analyzes PCR test data in real time to support clinical decision-making for medical staff. Based on PCR data uploaded from each hospital, ▲ regional infection trends ▲ hospital positivity rates ▲ multiple infection patterns are analyzed, and more than 40 kinds of statistical tools for clinical support are provided. Through this, medical staff can compare and analyze patient-specific infection patterns and infection rates in the surrounding areas, and establish more specific and data-based treatment strategies.
With the participation of ADLM 2025, Seegene will provide opportunities for advance experiences of CURECA™ and STAGORA™, which will become a new diagnostic paradigm, and expand global partnerships. CURECA™ has already received great attention at the European Society for Clinical Microbiology Infectious Diseases (ESCMID Global 2025) in April, and has also established local subsidiaries such as Seegene Technologies and Seegene Cureka to strengthen research and production in the United States.
"CURECA™ and STAGORA™ will be the ultimate criteria for redefining diagnostic standards in healthcare sites around the world, beyond just testing equipment and software," a Seegene official said. "We will continue to share with our customers the technology assets that Seegene has developed and continue to drive fundamental innovation in the global diagnostic ecosystem." he said.
This article was translated by Naver AI translator.
